Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Long Term Safety Study of PRALUENT
NCT03694197 · Regeneron Pharmaceuticals · PHASE4 · terminated · last registry update 2021-06-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated in other studies.” | – | Registry record, Regeneron Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-04Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran sodium 300 mg + Placebo (NCT05360446)
- 2022-04-13Phase 3 first posted: Shanghai Junshi Bioscience Co., Ltd., Ongericimab + Placebo (NCT05325203)
- 2022-02-17Results posted on the registry: University of Florida, Evolocumab (NCT03096288)
- 2022-02-10Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT05234775)
- 2022-02-10Results posted on the registry: LIB Therapeutics LLC, LIB003 (NCT03847974)
- 2022-01-14Results posted on the registry: Amgen, Evolocumab (NCT02624869)
- 2021-11-24Results posted on the registry: Amgen, Evolocumab + Placebo (NCT03570697)
- 2021-10-11Results posted on the registry: Marja-Riitta Taskinen, Evolocumab (NCT02948777)
- 2021-09-16Also stopped (terminated): Minneapolis Heart Institute Foundation, Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection (NCT03542110)
- 2021-09-01Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran sodium 300 mg + Placebo (NCT05030428)
- 2021-08-20Results posted on the registry: Amgen, evolocumab + placebo (NCT03433755)
- 2021-08-13Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep + Inclisiran (NCT05004675)
- 2021-07-20Phase 3 first posted: Beijing Anzhen Hospital, PCSK9 inhibitors and statins with or without ezetimibe + Statins with or without ezetimibe (NCT04968509)
- 2021-06-29Results posted on the registry: Regeneron Pharmaceuticals, Alirocumab + Placebo (NCT03156621)
- 2021-06-28Phase 3 first posted: Collegium Medicum w Bydgoszczy, Evolocumab + Saline solution (NCT04941105)
- 2021-06-18Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran (NCT04929249)
- 2021-05-07Results posted on the registry: Regeneron Pharmaceuticals, Praluent (Alirocumab) + Placebo (NCT02957682)
- 2021-05-05Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran (NCT04873934)
- 2021-04-01Results posted on the registry: Columbia University, Evolocumab (NCT03331666)
- 2021-04-01Also stopped (terminated): Columbia University, Evolocumab (NCT03331666)
- 2021-03-19Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Background lipid lowering therapy (NCT04807400)
- 2021-03-19Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04806893)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797104)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04798430)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797247)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision